The reduced expression of CD49d and CXCR4 and inhibition of CLL‐cell migration under the influence of SDF‐1α (Figure 2C) following ONC‐212 treatment suggest that, similar to the BCR‐targeted agents, ONC‐212 may reduce the migratory capacity of CLL cells and prevent their retention within the lymph nodes. Here, BCR is linked to B-cell chronic lymphocytic leukemia.